IGXT News 0.8800 Intelgenx Technologs (IGXT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intelgenx Technologs (IGXT) 0.8800 $IGXT

IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update
GlobeNewswire - Tue Mar 11, 7:32AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company" today announced financial results for its fiscal year ended December 31, 2013 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated.

IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines.

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL" of the U.S. Food and Drug Administration ("FDA" for the New Drug Application ("NDA" for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines.

IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
GlobeNewswire - Wed Feb 26, 7:42AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA" from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL(R), IntelGenx' first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.

IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product
GlobeNewswire - Mon Feb 24, 7:08AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm(TM) tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.

IntelGenx Technologies Report Delivers Analyst Opinion and Fundamental Data
PR Newswire - Wed Feb 05, 6:00AM CST
NEW YORK, Feb. 5, 2014 /PRNewswire - IntelGenx Technologies Corp (OTC: IGXT), is a drug delivery company, that engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market.

IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data

11th Trust Dialogue - Impunity Number One Enemy of Democracy-Ekeweremadu
by Ronald Mutum - All Africa Global Media - Fri Jan 17, 1:21AM CST
The Deputy Senate President, Ike Ekeweremadu has said impunity in politics is the number one enemy of Nigeria's democracy.

IntelGenx Announces Additional Development and Commercialization Agreement With Par Pharmaceutical, Inc. for Two More Products
GlobeNewswire - Mon Jan 13, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company" , a Canadian drug delivery company focusing on oral drug delivery, today announced that it has entered into another development and commercialization agreement with Par Pharmaceutical, Inc. ("Par" for two new products utilizing IntelGenx' proprietary oral drug delivery platforms.

IntelGenx Grants Stock Options
GlobeNewswire - Thu Jan 09, 10:34AM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company" (TSX-V:IGX) (OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire 120,000 common shares under the 2006 Stock Option Plan, as amended. The options were granted to the President and Chief Executive Officer, Dr. Rajiv Khosla in accordance with his employment agreement.

IntelGenx Closes $3.5 Million Public Offering
GlobeNewswire - Mon Dec 16, 2:35PM CST
IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx" , a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm(TM) technology, as well as oral controlled-release products, announced today that it has closed a registered public offering to raise gross proceeds of approximately $3.5 million.

IntelGenx Announces Public Offering of $3,500,000 of Common Stock
GlobeNewswire - Thu Dec 12, 7:05AM CST
IntelGenx Technologies Corp. (OTCQX:IGXT) (TSX-V:IGX) ("IntelGenx" , a drug delivery company focused on the development of novel oral rapidly disintegrating delivery systems including its proprietary VersaFilm(TM) technology, as well as oral controlled-release products, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $3.5 million of securities in a registered public offering. IntelGenx has agreed to sell to institutional investors an aggregate of 7,920,346 shares of its common stock at $0.4419 per share. Additionally, investors will receive warrants to purchase up to 7,920,346 shares of common stock at an exercise price of $0.5646 per share for a term of five years.

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013
M2 - Fri Nov 22, 3:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/l62htg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013" report to their offering. 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure). Scope - A snapshot of the global therapeutic scenario for Congestive Heart Failure (Heart Failure). - A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson Amgen Inc. AstraZeneca PLC Athersys, Inc. GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. Bioheart, Inc. Neurocrine Biosciences, Inc. Novartis AG Acorda Therapeutics, Inc. Dong-A Pharmaceutical Co., Ltd. Les Laboratoires Servier Bayer AG Celladon Corporation IntelGenx Technologies Corp. Mesoblast Ltd Palatin Technologies, Inc. Cardio3 BioSciences SA La Jolla Pharmaceutical Company and many more... For more information visit http://www.researchandmarkets.com/research/l6...tive_heart About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

IntelGenx Reports Q3, 2013 Results and Corporate Development Highlights
GlobeNewswire - Fri Nov 08, 5:05AM CST
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced financial results for the three and nine months ended September 30, 2013 and provided an update on operational developments. All amounts are in U.S. dollars, unless otherwise stated.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Venezuela's Political Shift and Its Impact on Global Oil Markets

Updated Category News Views 122

Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....

Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative

Updated Category News Views 27

The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...

Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement

Updated Category News Views 74

DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...

Continue Reading
Insights into the Growth of the Global Fondant Market Trends

Updated Category News Views 230

Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...

Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details

Updated Category News Views 110

Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...

Continue Reading